Premium
Treatment of mycosis fungoides with recombinant interferon‐αza 2 alone and in combination with etretinate
Author(s) -
THESTRUPPEDERSEN K.,
HAMMER R.,
KALTOFT K.,
SØGAARD H.,
ZACHARIAE H.
Publication year - 1988
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/j.1365-2133.1988.tb02600.x
Subject(s) - etretinate , mycosis fungoides , dermatology , medicine , lymphoma , psoriasis
SUMMARY Eleven patients with mycosis fungoides (MF) were treated with recombinant alpha‐intcrfcron (rIFN‐α2a 2 ) in combination with etretinate (seven patients) or alone. One patient, who also received etretinate, went into complete remission and remained without signs of MF after 18 months. Six patients experienced partial remission; one of these was treated with rIFN‐α2a alone and was clinically in complete remission, but had still a pteomorphic skin infiltrate. Two patients were non‐evaluable, and two stopped therapy due to progressive disease. Five patients discontinued therapy due to side‐effects although three had partial remission of their disease. Only four patients received 12 months therapy. The study shows that rIFN‐α2a in combination with etretinate or alone can induce remission of MF.